卵巣癌のうち、漿液性癌、類内膜癌ではFGF3, FGF4コピー数増幅が少数ながら認められ、分子標的薬ソラフェニブの効果が期待できる可能性が示唆されたが、明細胞癌では殆ど認められなかった。卵巣癌に対するソラフェニブは本邦では臨床投与は殆どなされておらず、少数例の薬剤感受性試験においてはソラフェニブ感受性症例はなく、上記について臨床的には実証されていない。子宮体癌や子宮頸癌ではFGF3, FGF4コピー数増幅を認めた症例は少なく、細胞株ではコピー数増幅は認められないことから、ソラフェニブが有効な症例は殆どないか、少なくともFGF3, FGF4コピー数増幅での効果予測に限界があることが示唆された。
Among ovarian cancer, some patients with serous carcinoma and endometrioid carcinoma had the FGF3 and FGF4 copy number amplification, and it is suggested that the effect of molecular target therapy with sorafenib could be effective for them. However, most patients with clear cell carcinoma had no amplification of FGF3 and FGF4 copy number. Sorafenib is not used clinically for patients with ovarian cancer in Japan. Since there were no sorafenib-sensitive cases in drug sensitivity tests conducted in several cases, no clinical demonstration has been made on the above so far. There were few patients with endometrial cancer and cervical cancer who had the FGF3 and FGF4 copy number amplification. , and no copy number amplification was observed in endometrial and cervical cancer cell lines. Therefore, it was suggested that there were few cases where sorafenib was effective, or at least there was a limit to the prediction of the effect using FGF3 and FGF4 copy number amplification.

研究種目 : 基盤研究(C)(一般)
研究期間 : 2016～2018
課題番号 : 16K11153
研究分野 : 婦人科腫瘍学